Sofalcone inhibits osteoclastogenesis through Keap1/Nrf2 signaling activation and mitigates ovariectomy-induced bone loss

Haibo Liang, Qihang Wu, Tian Hua, Tianyong Hua, Yiqi Chen, Jiangtao Luo, Jiansen Miao, Hong Su, Yang Shu, Jiake Xu, Xiangyang Wang, Haiming Jin
In: International Immunopharmacology · 2025 · vol. 166 , pp. 115589 · doi:10.1016/j.intimp.2025.115589 · PMID:41005145 · W4414579066
article OA: hybrid CC0
🔓 Open OA copy View on OpenAlex View on PubMed View at publisher

Abstract

Osteoporosis, a metabolic bone disorder, predominantly affects postmenopausal women and frequently results in pathological fractures. Current treatments for this condition often entail significant side effects, limiting their clinical utility. Sofalcone (SFC), a phenolic derivative isolated from the Chinese herb Sophora tonkinensis, has demonstrated antioxidative, anti-inflammatory, and anti-ulcer capabilities, has been less studied for its effects on osteoclasts and osteoporosis. Our in vitro studies reveal that SFC inhibits osteoclastogenesis and reduces osteoclastic bone resorption. It achieves this by enhancing the Kelch-like ECH-associated protein 1 (Keap1)/nuclear factor erythroid 2-related factor 2 (Nrf2) signaling pathway, which boosts the expression of antioxidant genes, decreases the production of reactive oxygen species (ROS), and suppresses activation of the mitogen-activated protein kinase (MAPK) signaling pathway. Further investigations using ovariectomized (OVX) mice have shown that SFC mitigates bone density loss and improves bone microarchitecture, suggesting its utility as both a preventive and therapeutic measure against osteoporosis.

My notes (saved in your browser only)

Citation neighborhood (no data yet)

We don't have any in-corpus citations linked to this paper yet. This is a recent paper (2025) — citers typically take a year or two to land, and the OpenAlex reference graph may still be filling in.

References (47)

Source provenance

openalex
last seen: 2026-06-10T17:14:06.276822+00:00
License: CC0 · commercial use OK